En Bloc Bladder Tumor Resection: Prospective Randomized Study
1 other identifier
interventional
300
1 country
1
Brief Summary
INTRODUCTION Bladder tumor is the second most common neoplasm in the genitourinary tract. Most cases of ex novo diagnosis of bladder cancers are present as non-invasive muscle tumors, which are treatable through endourological procedures. The current standard is based on conventional transurethral resection of bladder tumor, although high rates of recurrence have been reported following resection of the primary tumor. Given the importance of a correct initial diagnosis in these cases, en bloc transurethral resection has developed over the past 2 decades. This technique was born, according to the literature, with 3 main objectives: to improve the quality of the surgical piece for its anatomopathological reading, reduce the rate of postoperative complications and reduce the rate of relapses in the surgical bed. This technique is used as a common practice of tumor resection in other centers and has been shown in multiple publications that it does not increase surgical risk or negatively affect cancer results. OBJECTIVE The objective of our study is to compare feasibility, perioperative complication rate, accuracy of staging and recurrence/progression rates when performing en bloc resection by means of different energies: monopolar, bipolar and laser energy. MATERIAL AND METHODS Between April 2018 and June 2021, a prospective randomized study will be conducted including patients undergoing a transurethral resection of initial or recurrent bladder tumor, either unifocal or multifocal. Patients with tumors less than 3 cm and with less than 3 tumors shall be included if multiple. Patients with more than 3 tumors or tumors over 3cm, those with evidence of invasive muscle tumor(cT2) or those with evidence of remote metastasis, whether lymphatic or organic, will be excluded. Patients will be randomized into two groups:
- Group 1 (test): en bloc resection (n-180). It will be divided into 3 subgroups according to the energy used (monopolar, bipolar, laser energy).
- Group 2 (control): Conventional transurethral resection (n-120). It will be divided into 2 subgroups depending on the energy used (monopolar or bipolar). A fact sheet will be given to the patient about the study and the signature of the informed consent will be requested in order to be included. The patient will be free to leave the study at any time without having to provide any justification and without affecting the treatment, intervention and follow-up that must be carried out. The processing and storage of samples will be carried out in the pathological anatomy laboratory, according to standard clinical practice. Patients will be monitored according to the usual clinical practice protocol (minimum 5-year follow-up), included in the non-muscle invasive bladder tumor protocols of the Puigvert Foundation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2018
CompletedFirst Submitted
Initial submission to the registry
January 12, 2021
CompletedFirst Posted
Study publicly available on registry
January 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2026
CompletedJanuary 15, 2021
January 1, 2021
3.2 years
January 12, 2021
January 13, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Staging of bladder tumor
Evaluation of muscle presence in the specimen
Three years
Secondary Outcomes (8)
Intraoperative complications
Three years
Rate of planned adjuvant treatment
Three years
Post-operative complications
Three years
Substaging T1 bladder cancer
Three years
Recurrence-free survival
Through study completion, an average of five years
- +3 more secondary outcomes
Study Arms (2)
En bloc
EXPERIMENTALEn bloc transurethral resection of the bladder
Conventional
ACTIVE COMPARATORConventional transurethral resection of the bladder
Interventions
En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy
Conventional transurethral resection of bladder tumor using monopolar and bipolar energy
Eligibility Criteria
You may qualify if:
- Unifocal primary or recurrent bladder cancer with size less or equal than 3 cm
- Multifocal primary or recurrent bladder cancer less or equal than 3 lesions and with size less or equal than 3 cm
You may not qualify if:
- Evidence of \> 3 tumors or \> 3 cm
- Computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (cT2 or higher)
- Computed tomography/magnetic resonance evidence of distant metastases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Fundacio Puigvertlead
- KARL STORZ Endoscopy-America, Inc.collaborator
Study Sites (1)
Fundacio Puigvert
Barcelona, 08025, Spain
Related Publications (1)
Gallioli A, Diana P, Fontana M, Territo A, Rodriguez-Faba O, Gaya JM, Sanguedolce F, Huguet J, Mercade A, Piana A, Aumatell J, Bravo-Balado A, Algaba F, Palou J, Breda A. En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial. Eur Urol Oncol. 2022 Aug;5(4):440-448. doi: 10.1016/j.euo.2022.05.001. Epub 2022 May 23.
PMID: 35618567DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chief of the Uro-Oncology Division and Kidney Transplant Unit
Study Record Dates
First Submitted
January 12, 2021
First Posted
January 15, 2021
Study Start
April 1, 2018
Primary Completion
June 1, 2021
Study Completion
April 1, 2026
Last Updated
January 15, 2021
Record last verified: 2021-01